ArticleJournal of vascular surgery cases and innovative techniques2026
Cholesterol embolization syndrome: A case report and literature review.
Article in Journal of vascular surgery cases and innovative techniques, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholesterol embolization syndrome is a clinical condition caused by cholesterol crystals dislodged from atherosclerotic plaques, leading to distal arterial occlusion and subsequent organ ischemia. We present a case of a 61-year-old male who developed blue toe syndrome, reticular livedo, and gastrointestinal bleeding 1 week after aortic interventional therapy for intermittent claudication. The patient exhibited eosinophilia and multiorgan dysfunction. Diagnosis was confirmed by fundoscopic examination revealing a cherry-red spot at the macula. This case, combined with a literature review, discusses the clinical features, diagnostic criteria, and therapeutic strategies of this disease to enhance clinician awareness. The patient was followed for 3 months with ongoing follow-up thereafter, during which renal function partially recovered from stage 4 to stage 3b chronic kidney disease with conservative management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.